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Introduction:
Melanoma is a relatively common neoplasm which is increasing in incidence. Melanoma appears as a variegated irregular macu-
lopapular lesion usually on the skin, but possibly on mucosae, conjunctiva, orbit, nails and oesophagus. They may be black, 
brown, red-blue, grey or unpigmented.  Histologically they are larger than nevi cells with irregular nucleoli and eosinophilic 
nucleoli. [1] Melanoma incidence in Malta is lower than that in northern Europe and is similar to that in southern Europe. How-
ever, incidence appears to be increasing. . In a study done between the years 2000-2004 the rates for invasive melanoma were 
of 8.81 per 100,000 (males) and 7.29 per 100,000 (females). A relatively high proportion of patients present with thick lesions 
emphasising the importance of continued efforts to diagnose cases earlier. [2]
Aim:
The aim of this article is to make the reader aware of the importance of early detection and prevention of melanoma, to highlight 
the risk factors for developing melanoma and to outline the way in which melanoma is diagnosed, treated and followed up. 
Case Presentation:
A 20 year old male student initially presented at dermatologist with a pigmented macular skin lesion on the right upper posterior 
thigh. The lesion was painless, asymmetric with colour variation from pink to brown. The lesion was relatively small in size, with 
a diameter of approximately 10mm x 7mm.  A total skin investigation was performed and the patient did not have many nevi. On 
palpation the regional lymph nodes did not appear enlarged. There was no history of recent weight loss. The patient is a known 
asthmatic, and is on salbutamol (SABA) for asthma control. There are no other known chronic diseases. 
Family History: 
There was no previous history of melanoma and no family history for melanoma. 
Social history:
The patient is a full time student. There is no history of smoking or alcoholism. When the patient was asked about sun exposure, 
he couldn’t recall any severe sunburn in childhood, and there isn’t a particularly high tendency to tan. The patient also does not 
spend a lot of time in the sun, and has a skin type III18.
Diagnostic considerations: [3]
• Malignant Melanoma
• Benign melanocytic lesion
• Dysplastic nevus
• Blue nevus
• Epithelioid (Spitz) tumor
• Pigmented spindle cell nevus of Reed
Investigations:
The patient first underwent a surgical excision of the lesion (excision biopsy). Excision was performed after the lesion was anes-
thetized via local anaesthesia. A small amount of surrounding tissue was removed as well to ensure that any possible malignant 
cells were excised. The sample was sent for histological investigations at the pathology lab. 
A skin ellipse, measuring 20mmx9mmx2mm, bearing a slightly raised, lightly pigmented lesion measuring 10mmx7mm, was 
excised. On microscopy the section showed nested and single atypical melanocytes at the dermal-epidermal junction, above the 
junction as well as infiltrating the dermis where they reached the mid reticular dermis. The tumour had the overall configuration 
of a naevus and the tumour cells had a nevoid appearance. However, marked nuclear atypia was present throughout the tumour 
including at it deepest aspect. There was no ulceration. There was no host inflammatory response to the tumour. The excision of 
the tumour was complete.
The lesion was confirmed to be an invasive nevoid melanoma Clarke stage IV (Tumour extends between bundles of collagen of 
reticular dermis (extends into reticular dermis)), T classification pT3aN0 (AJCC staging), and a Breslow thickness of 2.19mm, the 
mitotic count was of 0/mm [2] [4] [5]  
Following diagnosis of melanoma a sentinel lymph node biopsy (SLNB) was performed for staging purposes. This is a minimally 
invasive technique to assess regional lymph node status in patients with malignancy. Any region of skin drains to a particular 
group of lymph nodes, but first the lymphatics drain through the sentinel node. Therefore it follows that if melanoma has metas-
tasised it will first affect the sentinel node.   
Identifying the Sentinel node involves two techniques. A gamma radiation emitting sulphur colloid is injected around the tumour 
before the operation and then the gamma emitting node is identified, and a vital blue dye (isosulphan blue) is injected intrader-
mally at the time of surgery and the blue node is then identified. The two techniques are usually used together to ensure that the 
correct node is in fact identified6.
The specific and limited removal of the sentinel node allows one to predict metastasis and reduces surgical insult and morbidity 
compared with conventional lymphatic clearance 6. Sentinel lymph node status is the most important independent prognostic 
factor in terms of disease progression and melanoma-specific survival.
The Sentinel node was removed from the right groin, and results were as follows: ‘A portion of fatty tissue measuring 10mm x 
12mm x 9mm. On sectioning, 2 nodules are present, each measuring 7mm in maximum dimension. The diagnosis was of benign 
reactive lymph node changes, mostly sinus histiocytosis. No metastases were present. 
Treatment:
The only procedure carried out for melanoma is a wider skin excision if there is no metastasis, this is done to decrease chances of 
local recurrence. This procedure was performed at the same time as the SNLB for logistical convenience and to because a wider 
excision before an SNLB would alter the lymphatics of the area rendering an SNLB impossible. 
The wider skin excision was done with a skin ellipse including subcutaneous tissue measuring 57mm x 35mm x 15mm being 
excised (margins 3cm). The diagnosis was of no evidence of residual melanoma. 
Follow up:
The patient is being followed up through outpatient appointments every 3 months for the next 2 years, every 6 months for the 2 
years following those and then at least once every year for life. This follow up involves history and physical examination with 
special emphasis on skin and lymph nodes. 
Discussion:
What is melanoma?
Melanoma is a malignant tumour of melanocytes, which are of neural crest origin. The most common forms of skin cancer are 
basal cell skin cancer, squamous skin cancer and melanoma.  Melanoma is the least common of these. However, it causes the 
highest rate of mortality of the three. It is the second most common cancer in teenagers and young adults. 
Melanomas have two growth phases, a radial phase during which malignant cells grow in a radial fashion in the epidermis and a 
vertical phase in which the malignant cells invade the dermis and develop the ability to metastasise. 
There are four main subtypes of melanoma, namely the superficial spreading melanoma (about 80%), nodular melanoma, lentigo 
maligna melanoma and acral lentiginous melanoma. Superficial spreading melanoma can occur anywhere and is characterised by 
slow, radial growth. Nodular melanoma can also occur anywhere, but is more common in men and exhibits rapid growth with an 
early vertical growth phase. This makes it more aggressive than superficial spreading melanoma. Amelanotic nodular melanoma 
is possible (5% of nodular melanomas). Lentigo maligna melanoma occurs in elderly with a history of sun exposure. It presents 
as large lesions on the face or neck, often arising from a precancerous lentigo maligna (Hutchinson’s freckle). Acral lentiginous 
melanoma is the most common type of melanoma in coloured people and typically occurs on the palms, soles or under the nails. 
Rarely, melanoma may also develop on the eyes (ocular melanoma) or any mucosa (mucosal melanoma). Mucosal melanomas 
tend to be very aggressive. Ocular melanoma is the commonest type of ocular malignancy. 
Risk Factors
The risk factors for melanoma include fair, sun-sensitive skin that burns rather than tans, many moles—more than 50, moles 
which are large or unusual in colour or shape, a personal history of melanoma, excessive exposure to UV from the sun or sun 
beds and a history of severe sunburns. In fact, about 80% of melanomas occur in white skinned people. The disease is also ex-
ceedingly common in albinos.  
Close family history of melanoma, freckling (especially of the upper back), red or blond hair, blue, green or grey eyes and the 
presence of solar keratosis are also risk factors for developing melanoma. Each of these risk factors increases the risk of mela-
noma by about 3.5 times. [9]
In melanoma, as with all other skin disorders, it is important to ask about occupation and hobbies as part of the history in order to 
reveal any possible exposures that may have contributed to the disease process. People who work in the sun all day are at a higher 
risk of developing Lentigo malignant melanoma and some studies have shown that exposure to insecticides such as carbaryl may 
also increase the risk of developing melanoma. [10]
The Gene CDKN2A has also been implicated in the development of malignant melanoma.  This gene generates a variety of 
transcripts varying in their first exon. Two proteins produced by these transcripts have been found to function as CDK4 Kinase 
inhibitors. Another transcript is known to contain an alternate open reading frame (ARF) that specifies a protein which functions 
as a stabilizer of the tumour suppressor p53. All these proteins share a common functionality in cell cycle G1 control and muta-
tions in this tumour suppressor gene have been correlated with various cancers including malignant melanoma. [19] However, 
people with apparently no risk factors and those with darker skin can also be affected by melanoma, as was the case with this 
patient. A possible explanation is the general immunosuppressive effect of sunlight, leading to an increased risk of developing 
melanoma due to lack of immunological tumour surveillance. This risk seems to be especially highlighted in individuals who are 
unaccustomed to sunlight exposure, and only receive intermittent doses of strong sunlight. This explanation would also account 
for melanoma that occurs in areas not normally exposed to sunlight, as in this cas. [11] [12]
Detection, Clinical Features and Prevention
Self detection or detection by a family member of the melanoma has very high success rates with research showing that 53% of 
melanomas are discovered by the patients themselves and a further 17% by their family members. A skin self-exam is simple and 
takes only 10-15 minutes once per month8. A mirror can be used to visualise hard to see places. 
Melanomas are usually dark brown or black, and they may be flat or raised. Many melanomas arise from a pre-existing melano-
cytic naevus (at least 50%13), so it is essential to report any recent changes in a mole to a doctor. 




• Diameter (greater than 6 mm)
• Evolving over time 
Other features of a pigmented lesion that are suggestive of advanced melanoma include bleeding, ulceration, satellite or in-transit 
lesions, sensations of local discomfort and the presence of a red halo around the lesion. Melanomas (especially the superficial 
spreading type) may also show patches of regression. 
Satellite lesions are lesions occurring around the main lesion due to lateral spread of cells via the dermal lymphatics, while in-
transit lesions occur along the route of lymphatic drainage of the naevus. 
Although spread to regional lymph nodes occurs quite quickly, haematogenous spread tends to occur late. However, when it does 
occur it is unpredictable and tends to be aggressive. 
Protection of the skin by staying out of the sun during midday hours (11am – 4pm), wearing protective clothing and wearing 
sunscreen with an SPF of 50, and which protects against UVA and UVB, are all important in preventing melanoma. Sunscreen 
should not be used to prolong exposure, and it is important to reapply sunscreen at 2 hour intervals. Protective clothing should 
include hat, sunglasses and preferably a long sleeved shirt and trousers. Tanning beds and sunlamps should also be avoided as 
they expose the user to harmful UVA and UVB rays14. 
Educating the public on melanoma and how to prevent it is probably the best way to reduce the incidence of melanoma and other 
skin cancers [15]
Prognostic Features 
The importance of self examination of the skin cannot be emphasised enough as the prognosis for melanoma changes drastically 
for early lesions and more advanced lesions. The most accurate indicator of prognosis is the Breslow’s depth of the lesion. A Bre-
slow’s depth of less than 1mm has a 5 year survival rate of over 95%, and one of more than 4mm has only a 50% 5 year survival 
rate assuming there is no nodal or distant metastasis7. Amelanocytic melanomas have a worse prognosis than their melanocytic 
counterparts simply because they are often diagnosed late. This further emphasises the importance of early detection. 
The presence of satellite or in-transit lesions and ulceration of the lesion both make the prognosis worse. Also, males tend to do 
worse than females. As in this case, the absence/few mitotic bodies improve prognosis.
Finally, the presence of metastases has a huge impact on prognosis. A single positive node is associated with a 40% 10-year sur-
vival rate, while 2 positive nodes give a 13% survival rate. If distant metastases are found, there is only a 25% 2 year survival 
rate. [9]
Treatment Options
Treatment of melanoma is primarily surgical. In this case, an excision biopsy is performed (or an incision biopsy for an excep-
tionally larger lesions) to confirm the diagnosis and determine the Breslow thickness and Clark stage. Next, depending on the 
Breslow thickness, a clear margin (including subcutaneous tissue) needs to be excised: [9]
  Breslow Thickness (mm) Recommended Margin (cm)
   In Situ         0.5
     <1           1
     1-2         1-2
     2-4         2-3
     >4           3
It is important to have clear margins to lower the risk of local recurrence and eliminate undetected satellite lesions. 
Regarding lymph nodes, SLNB is the mode. This was in fact what was used in this case. In patients with melanoma of less than 
1mm depth SNLB is not recommended unless there are other poor prognostic factors like ulceration and high mitotic rate. If the 
SNLB is positive a radical lymph node dissection is recommended as this prolongs the disease few survival, although it does not 
affect the overall survival rate. [20]
Medical management is reserved for adjuvant therapy of patients with very advanced melanoma (Breslow >4mm). This was, 
hence, not required in this case. However, modified radiotherapy may reduce recurrence and improve survival rates. [9] Immu-
notherapy (interferon or interleukin) may be used in conjunction with chemotherapy or surgery to increase the immune system’s 
ability to recognise and destroy cancer cells. [16]  Chemotherapy is of limited usefulness, but is sometimes used in disease that 
has spread or to slow the progression of the disease, as in locally advanced melanoma with regional or in-transit metastasis, where 
surgery is not an option. 
Patients with distant metastases may consider radiotherapy or chemotherapy (dacarbazine), though these would have only a pal-
liative role. Surgery may be considered in oligometastatic disease, or to prevent pain or ulceration. Very advanced patients may 
consider enrolling in a clinical trial. [17] Melanoma vaccines are the best near term hope for improving mortality in patients 
with advanced disease. Currently trials are aimed at treatment of patients with advanced disease, but their relatively low toxicity 
makes them attractive for adjuvant therapy in stage I patients at high risk for recurrence. [21]  In short, melanoma with distant 
metastases is not normally curable, so efforts should be aimed at prevention and early detection of the disease.
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